Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO)
CONCLUSION: The trial reached its primary end point of biochemical control and PFS, suggesting a clinical advantage for SBRT in addition to first-line AAP treatment in patients with metastatic castration-resistant prostate cancer.PMID:37733977 | DOI:10.1200/JCO.23.00985
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Giulio Francolini Andrea Gaetano Allegra Beatrice Detti Vanessa Di Cataldo Saverio Caini Alessio Bruni Gianluca Ingrosso Rolando Maria D'Angelillo Anna Rita Alitto Matteo Augugliaro Luca Triggiani Silvana Parisi Gaetano Facchini Marco Banini Gabriele Simo Source Type: research
More News: Abiraterone Acetate | Allegra | Cancer | Cancer & Oncology | Clinical Trials | Prednisone | Prostate Cancer | Radiation Therapy